interest in the potential use of N9-GP as a single-dose OD treatment prompted a post hoc patient-level analysis from the paradigm 2 trial to describe the dosing and efficacy of N9-GP as an OD treatment.
Fifteen of 74 patients in paradigm 2 were enrolled to OD treatment, consisting of a single 40-IU/kg dose of N9-GP, with additional doses of 40 IU/kg as required. Thirteen patients (86.7%) had severe hemophilia (FIX <1 IU/dL) and 2 (13.3%) had moderate hemophilia (FIX 1-2 IU/dL). Twelve patients (80.0%) had target joint (TJ) bleeds at baseline. The study duration of OD treatment in paradigm 2 was 28 weeks.
Fourteen patients reported 143 bleeds, all mild/moderate in severity (Table 1) . Most bleeds (83.9%) were treated with a single dose of N9-GP, and the remainder with 2 or more doses (Table 1) . Considering patient-level data, seven patients had all 62 of their bleeds (100%) treated with 1 dose. Annualized bleeding rates in these patients were reduced by 37% from 26.1 prestudy to 16.5 on-study. Hemostatic response was rated excellent for 36 and good for 26 bleeds.
The other seven patients had at least one bleed treated with 2 or more doses of N9-GP. While 28.4% of their bleeds were treated with 2 or more doses (hemostatic response: 18, good; 5, moderate), 71.6% were still treated with only 1 dose (hemostatic response: 7, excellent; 49, good; 1, moderate; 1, not reported).
Two of the 7 patients experienced 11 recurrent TJ bleeds, 4 (36.4%) of which required treatment with 2 or more doses of N9-GP. One patient, 18 years of age, reported three elbow TJ bleeds in 2 months, which were treated with 1, 5, and 2 doses of N9-GP, respectively. The second patient, 27 years of age, was treated prophylactically with plasma-derived FIX (pdFIX) 100 IU/kg every 3 days prior to entering the OD arm of paradigm 2. He reported two bleeds in 2 weeks in his right ankle TJ; one TJ bleed was treated with 2 doses (1 for early rebleeding) and the second bleed was treated with 6 doses, after which the patient was withdrawn.
The other 5 of the 7 patients experienced 70 bleeds; 72.9% were treated with 1 dose (hemostatic response: 2, excellent; 47, good; 1, moderate; 1, not reported) and 27.1% with 2 or more doses (hemostatic response: 17, good; 2, moderate). Four of these five patients had previously received 2 or 3 high FIX doses (60-81 IU/kg) for treating a bleed before entering the study and reported 63 bleeds while on study, which accounted for 44% of all bleeds in the OD treatment arm (Figure 1 ). The average N9-GP dose in these four patients ranged from 41.7 to 71.1 IU/kg per bleed and FIX utilization was reduced by 56-80% compared with the patient's historical FIX utilization (Figure 1 ). The fifth patient was treated prestudy with 1 prescribed infusion of 34 IU/ kg pdFIX per bleed with unknown effectiveness and had seven bleeds while on study (6 treated with 1 dose of~40 IU/kg per protocol and 1 with 2 doses; mean 46.8 IU/kg per bleed).
This post hoc analysis from paradigm 2 supports an important potential role for N9-GP in the OD treatment of mild/moderate bleeds. Modeling based upon the Phase 1 pharmacokinetic study to achieve recommended FIX levels suggested by the World Federation of Hemophilia The recent Bridging Hemophilia Experiences Results and Opportunities into Solutions (B-HERO-S) study in patients with mild-moderate-severe hemophilia in the USA reported that increasing education about self-infusion may be of benefit to individuals, particularly those with mild/moderate hemophilia: treatment is typically given at a hemophilia clinic or hospital and/or patients need assistance from family members or health care professionals; fewer than 10% of patients reported that all their infusions were at home.
7 Delays in recognizing bleeds or receiving help with infusions may also impact outcomes over time. Specifically, B-HERO-S showed that pain, functional impairment, and anxiety/depression were present at higher-than-expected levels in patients with mild/moderate hemophilia B, including affected women, suggesting unmet needs in the management of this population and perhaps undertreatment of bleeding episodes. 8 Coupled with improved education to increase the recognition of bleeds, the ability to treat most bleeds with 1 dose with sustained FIX activity, within the World Federation of Hemophilia guidelines 5 recommendations over many days, offers a potential pathway to improved outcomes.
In conclusion, a single 40 IU/kg dose of N9-GP was effective as an OD treatment for most bleeds in patients with hemophilia B investigated in paradigm 2. For patients who required additional N9-GP doses, the majority had either recurrent TJ bleeds or a history of multiple high-dose treatment. A prolonged duration of treatment after bleeding and potential change to routine prophylaxis is typical for patients with recurrent TJ bleeds. For patients who may not have required additional dosing of rFIX/pdFIX based upon their phenotype or individual pharmacokinetics, the paradigm 2 analysis supports the predictive modeling that a change to N9-GP would likely be associated with fewer infusions and FIX utilization than rFIX/pdFIX.
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